“We believe the early clinical data for CTIM-76 provides encouraging early signs of antitumor activity for Context’s T cell engagers in solid tumors where many other approaches have failed due to material safety issues or lack of efficacy,” said Martin Lehr, CEO of Context. “We look forward to continuing to advance Context’s clinical trials and providing more detailed updates in 2026.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTX:
- Context Therapeutics Reports Q3 2025 Financial Results
- Context Therapeutics Advances in Cancer Treatment with CTIM-76 Study
- Context Therapeutics’ CT-95 Study: A Potential Game-Changer in Cancer Treatment
- Context Therapeutics Amends Sales Agreement with Leerink
- Context Therapeutics Regains Nasdaq Compliance